AlloSource Announces First Patient Enrolled In ProChondrix CR Cartilage Defect Study

CENTENNIAL, Colo., March 20, 2019 /PRNewswire/ -- AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced it has enrolled the first patient in a study titled A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee.

Chondral injuries impact over one million patients across the United States annually and this potentially debilitating condition can cause compromised mobility and a decline in quality of life. AlloSource's clinical study will evaluate the effectiveness of ProChondrix CR, a fresh cryopreserved osteochondral allograft, when used for cartilage defects in the knee.

AlloSource developed ProChondrix CR as a cost-effective, single-stage alternative to provide the necessary components for articular cartilage restoration.  Following cryopreservation, ProChondrix CR delivers high chondrocyte viability for up to two years (~94% avg.) and helps stimulate hyaline cartilage growth by providing live, functional cells and other biological components necessary for the repair and regeneration of damaged cartilage tissues. The extracellular matrix provides structural support for cell migration and proliferation along the graft-native tissue line promoting integration, while viable chondrocytes aid in cartilage repair by generating proteins that help promote chondrogenesis.

"This study and our clinical efforts underscore the ongoing need for a long-term solution for patients with cartilage damage," said Ross Wilkins, MD, AlloSource Senior Medical Director. "Providing advanced biologic solutions, like ProChondrix CR, to support patient healing is what motivates us every day. This is an important milestone for AlloSource as we advance our investment in the clinical use of tissue."

AlloSource is excited to partner with our research sites to focus on the long-term outcomes of using ProChondrix CR for the repair of symptomatic articular cartilage defects on the femoral condyle and the patella.   For more information, please visit ClinicalTrials.gov or contact [email protected].  

About AlloSource
AlloSource is dedicated to advancing the science and use of transplantable allogeneic cells and tissue through pioneering research in regenerative therapies. The organization offers life-saving and life-enhancing solutions in orthopedic, spine, burn and wound procedures to help restore patient health and mobility. As a world leader in cell-based products, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource's products bridge the proven science of allografts with the advanced technology of cells. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org.  

Media Contact
Sarah McLaughlin
AlloSource
720. 317. 2936
[email protected]

SOURCE AlloSource

Related Links

http://www.allosource.org